Patients' Preferences Related to Benefits, Risks, and Formulations of Schizophrenia Treatment.

Keywords

Pill, Medicine, Schizophrenia (object-oriented programming), Confidence interval, Extrapyramidal symptoms

References

• Assessing Preferences for Schizophrenia Outcomes: Comprehension and Decision Strategies in Three Assessment MethodsMartha Shumway, Tetine Sentell, Tandy L. Chouljian — 2003
• Use of the Internet for willingness-to-pay surveys: A comparison of face-to-face and web-based interviewsJytte Seested Nielsen — 2011
• Conjoint Analysis Applications in Health — How are Studies being Designed and Reported?Deborah A. Marshall, John F. P. Bridges, Brett Hauber — 2010
• Evidence‐based medicine: it’s not just about the evidenceLeslie Citrome — 2011
• A test of concordance between patient and psychiatrist valuations of multiple treatment goals for schizophreniaJohn F. P. Bridges, Lara Slawik, A Schmeding — 2013
• Application of the BRAT Framework to Case Studies: Observations and InsightsB Levitan, Elizabeth Andrews, Alicia Gilsenan — 2011
• Discrete Choice Experiments in Health Economics: A Review of the LiteratureMichael Clark, Domino Determann, Stavros Petrou — 2014
• The effects of response mode and importance on decision-making strategies: Judgment versus choiceRobert S. Billings, Lisa L. Scherer — 1988
• Factors That Affect Adherence to Bipolar Disorder Treatments: A Stated-Preference ApproachF. Reed Johnson, Semra Özdemir, Ranjani Manjunath — 2007
• Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-makingJan Volavka, Leslie Citrome — 2009
• Magnetic resonance imaging for the investigation of knee injuries: an investigation of preferences.Stirling Bryan, Martin Buxton, Robert S. Sheldon — 1998
• Can Patients Diagnosed with Schizophrenia Complete Choice-Based Conjoint Analysis Tasks?John F. P. Bridges, Elizabeth Kinter, A Schmeding — 2011
• Preference weights for cost-outcome analyses of schizophrenia treatments: comparison of four stakeholder groups.Martha Shumway — 2003
• Estimating importance weights for the IWQOL-Lite using conjoint analysisBrett Hauber, Ateesha F. Mohamed, F. Reed Johnson — 2010
• Patient Benefit-Risk Preferences for Targeted Agents in the Treatment of Renal Cell CarcinomaAteesha F. Mohamed, Brett Hauber, Maureen P. Neary — 2011
• Measuring preferences for schizophrenia outcomes with the time tradeoff methodMartha Shumway, Tandy L. Chouljian, Cynthia L. Battle — 2005
• A Bayesian Truth Serum for Subjective DataDražen Prelec — 2004
• How Do Physicians Weigh Benefits and Risks Associated with Treatments in Patients with Osteoarthritis in the United Kingdom?N K Arden, Brett Hauber, ATEESHA F. MOHAMED — 2012
• Testing for the survey mode effect on contingent valuation data quality: A case study of web based versus in-person interviewsCristina Marta-Pedroso, Helena Freitas, Tiago Domingos — 2007
• Preferences for schizophrenia treatment outcomes among public policy makers, consumers, families, and providers.Martha Shumway, Teri Saunders, David L. Shern — 2003

Cited by

• What influences persistence with medicines? A multinational discrete choice experiment of 2549 patients.Emily Holmes, Valerie L. Morrison, Dyfrig Hughes — 2016
• Physician and patient benefit–risk preferences from two randomized long-acting injectable antipsychotic trialsEva G. Katz, Brett Hauber, Srihari Gopal — 2016
• Characterizing outcome preferences in patients with psychotic disorders: a discrete choice conjoint experiment.Robert B. Zipursky, Charles E. Cunningham, Bailey Stewart — 2017
• Using Discrete Choice Experiments to Inform the Benefit-Risk Assessment of Medicines: Are We Ready Yet?Caroline Vass, Katherine Payne — 2017
• Investigating service features to sustain engagement in early intervention mental health servicesMackenzie Becker, Charles E. Cunningham, Bruce K. Christensen — 2019
• Development of a stated-preference instrument to prioritize treatment goals in recent onset schizophreniaKathleen Beusterien, Elcie Chan, Pedro Such — 2017
• Shared decision making in mental health: the importance for current clinical practiceVictoria Alguera-Lara, Michelle M. Dowsey, Jemimah Ride — 2017
• Patient preferences for important attributes of bipolar depression treatments: a discrete choice experimentDaisy Ng‐Mak, Jiat Ling Poon, Laurie Roberts — 2017
• Quantifying the treatment goals of people recently diagnosed with schizophrenia using best–worst scalingJohn F. P. Bridges, Kathleen Beusterien, Stephan Heres — 2018
• Efficacy and metabolic effects of lurasidone versus brexpiprazole in schizophrenia: a network meta-analysis.Daisy Ng‐Mak, Vanita Tongbram, Kerigo Ndirangu — 2018
• Discrete Choice Experiments in Health Economics: Past, Present and FutureVikas Soekhai, Esther W. de Bekker‐Grob, Alan R. Ellis — 2018
• The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder.Victor I. Reus, Laura J. Fochtmann, Oscar Bukstein — 2019
• Antipsychotic choice: understanding shared decision-making among doctors and patientsVivien Yeo, Michelle M. Dowsey, Victoria Alguera-Lara — 2019
• Benefit–risk evaluation: the past, present and futureJuhaeri Juhaeri — 2019
• A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and futureLeslie Citrome, Joseph P. McEvoy, Mark S. Todtenkopf — 2019
• Hospitalization risk in patients with schizophrenia treated with dose-equivalent antipsychotics.Daisy Ng‐Mak, Andrew Messali, Ahong Huang — 2019
• Gap between patients with schizophrenia and their psychiatrists on the needs to psychopharmacological treatment: A cross‐sectional studyKie Takahashi, Ryoko Yamazawa, Takefumi Suzuki — 2020
• Formulário de seguimento farmacoterapêutico a cuidadores de pacientes com esquizofrenia refratáriaAglaciene Lopes da Silva, Camila Granado de Bastos, Flavia Caires Domingos — 2020
• Pharmacotherapeutic follow-up form for caregivers of patients with refractory schizophreniaAglaciene Lopes da Silva, Camila Granado de Bastos, Flavia Caires Domingos — 2020
• Antipsychotic Treatment Experiences of People with Schizophrenia: Patient Perspectives from an Online SurveyMichael J. Doane, Martha Sajatovic, Peter J. Weiden — 2020

Related papers

• Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human.Bruno Pouzet, Tomas Mow, Mads Kreilgård — 2003
• Weight gain with atypical antipsychotics: evidence and insights.David C. Henderson — 2007
• Extrapyramidal symptoms induced by antipsychotic drugs and the preventionsFalin Qu — 2012
• Exercise and Worsening of Extrapyramidal Symptoms during Treatment with Long-Acting Injectable AntipsychoticsDavid D. Kim, Donna J. Lang, Darren E. R. Warburton — 2021
• Exercise-associated extrapyramidal symptoms during treatment with long-acting injectable antipsychotic medications: A case report.David D. Kim, Donna J. Lang, Darren E. R. Warburton — 2017
• Extrapyramidal symptoms are serious side-effects of antipsychotic and other drugs.Donald Blair, Alana Dauner — 1992
• Reversal of olanzapine-induced weight gain in a patient with schizophrenia by switching to asenapine: a case reportKosuke Okazaki, Kazuhiko Yamamuro, Taishiro Kishimoto — 2017
• Exploring the Relationships Between Antipsychotic Dosage and Voice Characteristics in Relation to Extrapyramidal SymptomsH. Kim, Seoyoung Kim, Subin Lee — 2024
• Update on neuropsychiatric symptoms of dementia: antipsychotic use.Raj K. Kalapatapu, Corbett Schimming — 2009